Cargando…
Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation?
The prevalence of AF in patients with coronary artery disease is high. The guidelines from many professional groups, including the European Society of Cardiology, American College of Cardiology/American Heart Association and Heart Rhythm Society, recommend a maximum duration of 12 months of combinat...
Autores principales: | Abdulrahman, Balen, Jabbour, Richard J, Curzen, Nick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Radcliffe Cardiology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331563/ https://www.ncbi.nlm.nih.gov/pubmed/37435601 http://dx.doi.org/10.15420/icr.2022.40 |
Ejemplares similares
-
Coronary Physiology Derived from Invasive Angiography: Will it be a Game Changer?
por: Gabara, Lavinia, et al.
Publicado: (2020) -
Impact of extracardiac vascular disease on outcomes of 1.4 million patients undergoing percutaneous coronary intervention
por: Bashar, Hussein, et al.
Publicado: (2022) -
Diagnostic Angiograms and Percutaneous Coronary Interventions in Pregnancy
por: Khaing, Phyo Htet, et al.
Publicado: (2020) -
OCT-guided Percutaneous Coronary Intervention in Bifurcation Lesions
por: Longobardo, Luca, et al.
Publicado: (2019) -
Percutaneous Coronary Intervention in Anomalous Right Coronary Artery: Ready to Implement in Clinical Routine?
por: Stark, Anselm W, et al.
Publicado: (2022)